S&P 500   5,089.24 (+0.04%)
DOW   39,100.32 (+0.08%)
QQQ   437.29 (-0.18%)
AAPL   182.57 (-0.98%)
MSFT   409.97 (-0.41%)
META   484.11 (-0.42%)
GOOGL   143.69 (-0.28%)
AMZN   174.22 (-0.21%)
TSLA   192.53 (-2.47%)
NVDA   798.09 (+1.62%)
NIO   5.45 (-6.84%)
AMD   176.74 (-2.82%)
BABA   75.94 (-0.24%)
T   16.80 (+1.27%)
F   12.16 (+0.33%)
MU   85.91 (+0.00%)
CGC   3.40 (+0.89%)
GE   153.30 (+1.07%)
DIS   107.65 (+0.01%)
AMC   4.47 (+1.13%)
PFE   27.82 (+0.98%)
PYPL   59.20 (+1.46%)
XOM   103.88 (-0.84%)
S&P 500   5,089.24 (+0.04%)
DOW   39,100.32 (+0.08%)
QQQ   437.29 (-0.18%)
AAPL   182.57 (-0.98%)
MSFT   409.97 (-0.41%)
META   484.11 (-0.42%)
GOOGL   143.69 (-0.28%)
AMZN   174.22 (-0.21%)
TSLA   192.53 (-2.47%)
NVDA   798.09 (+1.62%)
NIO   5.45 (-6.84%)
AMD   176.74 (-2.82%)
BABA   75.94 (-0.24%)
T   16.80 (+1.27%)
F   12.16 (+0.33%)
MU   85.91 (+0.00%)
CGC   3.40 (+0.89%)
GE   153.30 (+1.07%)
DIS   107.65 (+0.01%)
AMC   4.47 (+1.13%)
PFE   27.82 (+0.98%)
PYPL   59.20 (+1.46%)
XOM   103.88 (-0.84%)
S&P 500   5,089.24 (+0.04%)
DOW   39,100.32 (+0.08%)
QQQ   437.29 (-0.18%)
AAPL   182.57 (-0.98%)
MSFT   409.97 (-0.41%)
META   484.11 (-0.42%)
GOOGL   143.69 (-0.28%)
AMZN   174.22 (-0.21%)
TSLA   192.53 (-2.47%)
NVDA   798.09 (+1.62%)
NIO   5.45 (-6.84%)
AMD   176.74 (-2.82%)
BABA   75.94 (-0.24%)
T   16.80 (+1.27%)
F   12.16 (+0.33%)
MU   85.91 (+0.00%)
CGC   3.40 (+0.89%)
GE   153.30 (+1.07%)
DIS   107.65 (+0.01%)
AMC   4.47 (+1.13%)
PFE   27.82 (+0.98%)
PYPL   59.20 (+1.46%)
XOM   103.88 (-0.84%)
S&P 500   5,089.24 (+0.04%)
DOW   39,100.32 (+0.08%)
QQQ   437.29 (-0.18%)
AAPL   182.57 (-0.98%)
MSFT   409.97 (-0.41%)
META   484.11 (-0.42%)
GOOGL   143.69 (-0.28%)
AMZN   174.22 (-0.21%)
TSLA   192.53 (-2.47%)
NVDA   798.09 (+1.62%)
NIO   5.45 (-6.84%)
AMD   176.74 (-2.82%)
BABA   75.94 (-0.24%)
T   16.80 (+1.27%)
F   12.16 (+0.33%)
MU   85.91 (+0.00%)
CGC   3.40 (+0.89%)
GE   153.30 (+1.07%)
DIS   107.65 (+0.01%)
AMC   4.47 (+1.13%)
PFE   27.82 (+0.98%)
PYPL   59.20 (+1.46%)
XOM   103.88 (-0.84%)

AzurRx BioPharma (AZRX) News Today

Notice: This company has been marked as potentially delisted and may not be actively trading.
SourceHeadline
finance.yahoo.com logoHanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
finance.yahoo.com - April 19 at 9:11 AM
marketwatch.com logoFirst Wave BioPharma Shares Jump 21% on FDA Review of Adrulipase IND Filing
marketwatch.com - January 15 at 11:34 PM
seekingalpha.com logoFWBI First Wave BioPharma, Inc.
seekingalpha.com - September 16 at 8:55 PM
investing.com logoFirst Wave BioPharma Inc (FWBI)
investing.com - April 30 at 7:57 PM
reuters.com logoFirst Wave BioPharma Inc
reuters.com - October 1 at 8:38 AM
marketwatch.com logoAzurRx BioPharma Changes Name to First Wave BioPharma
marketwatch.com - September 21 at 3:26 PM
finance.yahoo.com logoAzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
finance.yahoo.com - September 21 at 3:26 PM
benzinga.com logoAzurRx BioPharma To Acquire First Wave Bio In Transformative $229 Million Deal; Significantly Expands GI and IBD Treatment Pipeline (NASDAQ: AZRX)
benzinga.com - September 14 at 5:42 PM
msn.com logoWhy AzurRx BioPharma's Stock Is Trading Higher Today
msn.com - September 14 at 5:42 PM
finance.yahoo.com logoAzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
finance.yahoo.com - September 14 at 5:42 PM
marketbeat.com logo
marketbeat.com - September 14 at 9:36 AM
apnews.com logoAzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave ...
apnews.com - September 14 at 8:34 AM
finance.yahoo.com logoAzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
finance.yahoo.com - September 14 at 8:34 AM
finance.yahoo.com logoAzurRx BioPharma To Acquire First Wave Bio For $229M
finance.yahoo.com - September 13 at 5:03 PM
nasdaq.com logoAzurRx Announces Acquisition Of First Wave Bio, And Creation Of First Wave BioPharma
nasdaq.com - September 13 at 12:03 PM
finanznachrichten.de logoAzurRx BioPharma, Inc.: AzurRx BioPharma Announces Reverse Stock Split
finanznachrichten.de - September 13 at 6:28 AM
finance.yahoo.com logoAzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
finance.yahoo.com - September 13 at 6:28 AM
finance.yahoo.com logoAzurRx BioPharma Announces Reverse Stock Split
finance.yahoo.com - September 10 at 5:50 PM
apnews.com logoAzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial ...
apnews.com - September 10 at 12:50 PM
nasdaq.com logoAzurRx Activates New Clinical Trial Sites In India For Gastrointestinal Infections COVID-19 Study
nasdaq.com - September 10 at 12:50 PM
finance.yahoo.com logoAzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
finance.yahoo.com - September 10 at 12:50 PM
markets.businessinsider.com logoDMC Recommends AzurRx Continues Gastrointestinal Infections COVID-19 Study
markets.businessinsider.com - September 9 at 9:55 AM
finance.yahoo.com logoAzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
finance.yahoo.com - September 9 at 9:55 AM
finance.yahoo.com logoAzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis
finance.yahoo.com - September 8 at 12:54 PM
ca.finance.yahoo.com logoAzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
ca.finance.yahoo.com - September 7 at 8:34 PM
finance.yahoo.com logoAzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 7 at 8:34 PM
fool.com logoAZURRX BIOPHARMA INC COM USD0.0001(AZRX)
fool.com - September 5 at 8:49 PM
marketwatch.com logoAzurRx BioPharma Shares Rally on MS1819 Study Results >AZRX
marketwatch.com - August 18 at 5:56 PM
finance.yahoo.com logoWhy AzurRx Stock Is Trading Higher After MS1819 Combo Therapy Data?
finance.yahoo.com - August 18 at 5:56 PM
apnews.com logoAzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial ...
apnews.com - August 18 at 7:35 AM
finance.yahoo.com logoAzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)
finance.yahoo.com - August 18 at 7:35 AM
finance.yahoo.com logoAzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819
finance.yahoo.com - August 17 at 8:44 AM
finance.yahoo.com logoAzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
finance.yahoo.com - August 12 at 3:08 PM
finance.yahoo.com logoAzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
finance.yahoo.com - August 10 at 7:50 AM
apnews.com logoAzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full ...
apnews.com - July 28 at 7:20 AM
benzinga.com logoAzurRx BioPharma shares are trading lower after the company announced it increased its previously announced bought deal offering to $5 million.
benzinga.com - July 24 at 6:03 PM
nasdaq.com logoAzurRx BioPharma, Inc. Common Stock (AZRX)
nasdaq.com - July 23 at 8:05 PM
finance.yahoo.com logoAzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 Million
finance.yahoo.com - July 22 at 11:20 PM
finance.yahoo.com logoAzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock
finance.yahoo.com - July 22 at 6:20 PM
Get AzurRx BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.



AZRX Media Mentions By Week

AZRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AZRX
News Sentiment

0.00

0.46

Average
Medical
News Sentiment

AZRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AZRX Articles
This Week

0

0

AZRX Articles
Average Week

Get AzurRx BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:AZRX) was last updated on 2/23/2024 by MarketBeat.com Staff